Your browser doesn't support javascript.
loading
Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease / 中国当代儿科杂志
Article in En | WPRIM | ID: wpr-928592
Responsible library: WPRO
ABSTRACT
Kawasaki disease (KD) is one of the common acquired heart diseases in under-5-year-old children and is an acute self-limiting vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for preventing coronary artery aneurysm in the acute stage of KD. However, glucocorticoid (GC), infliximab, and other immunosuppressants are options for the treatment of KD patients with a high risk of coronary artery aneurysm, no response to intravenous immunoglobulin and a confirmed diagnosis of coronary artery aneurysm. At present, there are still controversies over the use of GC in the treatment of KD. With reference to the latest research findings of KD treatment in China and overseas, this consensus invited domestic pediatric experts to fully discuss and put forward recommendations on the indications, dosage, and usage of GC in the first-line and second-line treatment of KD.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Coronary Aneurysm / Immunoglobulins, Intravenous / Consensus / Glucocorticoids / Mucocutaneous Lymph Node Syndrome Type of study: Guideline Limits: Child / Child, preschool / Humans Language: En Journal: Chinese Journal of Contemporary Pediatrics Year: 2022 Type: Article
Full text: 1 Index: WPRIM Main subject: Coronary Aneurysm / Immunoglobulins, Intravenous / Consensus / Glucocorticoids / Mucocutaneous Lymph Node Syndrome Type of study: Guideline Limits: Child / Child, preschool / Humans Language: En Journal: Chinese Journal of Contemporary Pediatrics Year: 2022 Type: Article